Pharmaceutical company Elan and its partner Biogen have submitted an application to the European Medicines Agency for the approval of Antegren as a treatment for Crohn's disease.
The companies have also presented new data from trials of the treatment at a conference in Prague.
They say the data show 'a sustained and clinically significant response' from Crohn's sufferers to 12 months of therapy with Antegren.
Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract. It affects a million people worldwide.
Elan and Biogen have already submitted applications in Europe and the US for approval of Antegren as a treatment for multiple sclerosis.
